Orphazyme prepares for USD 50m capital hunt after nightmare year
After a year that brought Orphazyme failed studies and a rejection from the FDA, the Copenhagen-based biotech firm is now planning to bring in USD 50m by issuing American Depositary Shares (ADSs).
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
Biotech business Orphazyme, which is based in Copenhagen, Denmark, is planning to raise USD 50m through an American Depositary Shares (ADSs) issuance, it reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme fails trial in muscle wasting disease
For subscribers
Orphazyme cuts guidance following FDA setback
For subscribers
